Citius Pharmaceuticals to Highlight its Phase 3 Clinical Trial Product Mino-Lok® at Benzinga Biotech Small Cap Conference on March 25

Rhea-AI Summary

Citius Pharmaceuticals will participate in the Benzinga Biotech Small Cap Conference on March 24-25, 2021, where Executive Chairman Leonard Mazur will discuss the Phase 3 trial of Mino-Lok®, an antibiotic solution for catheter-related bloodstream infections. The trial is progressing as planned, with full enrollment expected this year. The U.S. market opportunity for Mino-Lok® is projected at $750 million, with a worldwide potential of $1.5 billion. Investors can register for the conference via the provided event website.

Positive

• Mino-Lok® Phase 3 trial is proceeding according to plan.
• Anticipated full enrollment in the trial this year.
• Significant market opportunity of $750 million in the U.S. and $1.5 billion globally for Mino-Lok®.

Negative

• None.

CRANFORD, N.J., March 23, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, will participate in the virtual Benzinga Biotech Small Cap Conference being held March 24-25, 2021. Citius Executive Chairman, Leonard Mazur, will present on Thursday, March 25 at 2:55 pm ET. Investors may register for the conference at the event website.

During the corporate presentation, Mr. Mazur will discuss the Company's Phase 3 program for its lead product candidate Mino-Lok®, an antibiotic lock solution being developed to treat patients with catheter-related bloodstream infections (CRBSIs).

"We are eagerly awaiting the third interim efficacy analysis from our independent Drug Monitoring Committee regarding the Mino-Lok® Phase 3 trial in progress," said Mr. Mazur. "This pivotal trial is progressing according to plan, and we expect full enrollment this year. The antibiotic lock solution market is large and substantially underserved, with an estimated market opportunity of $750 million in the U.S. and over $1.5 billion worldwide."

Citius issued its most recent Letter to Shareholders in February, highlighting recent updates on its business and clinical developments as well as news for its pipeline of products. To read the letter please visit the Company's Investor Info website at ir.citiuspharma.com.

About Citius Pharmaceuticals, Inc.
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit www.citiuspharma.com.

Safe Harbor
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated are: our ability to successfully undertake and complete clinical trials and the results from those trials for our product candidates, including Mino-Lok®; the estimated markets for our product candidates and the acceptance thereof by any market; our need for substantial additional funds; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to attract, integrate, and retain key personnel; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; government regulation; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:
Andrew Scott
Vice President, Special Projects
(O) 908-967-6677 x105
(M) 646-522-8410
ascott@citiuspharma.com

 

View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-highlight-its-phase-3-clinical-trial-product-mino-lok-at-benzinga-biotech-small-cap-conference-on-march-25-301253709.html

SOURCE Citius Pharmaceuticals, Inc.

FAQ

What will Citius Pharmaceuticals present at the Benzinga Biotech Small Cap Conference?

Citius will present the Phase 3 trial progress of its product candidate Mino-Lok® at the conference.

When is Citius Pharmaceuticals' presentation at the Benzinga Conference?

The presentation is scheduled for March 25, 2021, at 2:55 pm ET.

What is Mino-Lok® used for?

Mino-Lok® is an antibiotic lock solution developed to treat catheter-related bloodstream infections.

What is the market opportunity for Mino-Lok®?

The U.S. market opportunity for Mino-Lok® is estimated at $750 million, with a global potential of $1.5 billion.

What do we know about the Phase 3 trial for Mino-Lok®?

The Phase 3 trial is progressing as planned, with full enrollment expected in 2021.